Propanc Biopharma, Inc. (PPCB) stock
PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
$1.94+0.02 (+1.09%)
Close on Nov 13, 2026Market cap $12.29MP/E –Yield –
Propanc Biopharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Propanc Biopharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$5.71M. For fiscal 2026 it was -$5.68M. The highest annual figure on record is -$128.65K in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$5.68M | – |
| FY2025 | Jun 30, 2025 | -$405.17K | – |
| FY2024 | Jun 30, 2024 | -$935.12K | – |
| FY2023 | Jun 30, 2023 | -$1.11M | – |
| FY2022 | Jun 30, 2022 | -$1.44M | – |
| FY2021 | Jun 30, 2021 | -$1.15M | – |
| FY2020 | Jun 30, 2020 | -$1.85M | – |
| FY2019 | Jun 30, 2019 | -$2.06M | – |
| FY2018 | Jun 30, 2018 | -$2.18M | – |
| FY2017 | Jun 30, 2017 | -$2.05M | – |
| FY2016 | Jun 30, 2016 | -$4.50M | – |
| FY2015 | Jun 30, 2015 | -$1.43M | – |
| FY2014 | Jun 30, 2014 | -$226.44K | – |
| FY2013 | Jun 30, 2013 | -$128.65K | – |
| FY2012 | Jun 30, 2012 | -$170.28K | – |
| FY2011 | Jun 30, 2011 | -$1.40M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$1.97M | – |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$1.60M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$1.14M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$999.14K | -5434.7% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$1.94M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$92.19K | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$96.20K | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $18.73K | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$235.52K | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$259.97K | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$102.81K | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$238.89K | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$333.46K | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$177.97K | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$192.74K | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$225.23K | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$509.32K | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$411.00K | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$314.21K | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$224.34K | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$486.76K | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$236.29K | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$468.00K | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$261.03K | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$179.95K | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$499.66K | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$207.05K | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$416.55K | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$726.33K | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$266.23K | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$737.02K | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$637.59K | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$419.20K | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$447.56K | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$658.76K | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$285.66K | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$785.67K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$601.56K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$444.45K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$321.03K | – |
See a number that looks wrong?